Loading...
•
Jun 30, 2022
Kodiak Sciences Q2 2022 Earnings Report
Reported business highlights and financial results for the second quarter of 2022.
Key Takeaways
Kodiak Sciences reported positive topline results from its Phase 3 pivotal study of tarcocimab tedromer in treatment-naïve patients with macular edema due to retinal vein occlusion. The net loss for the second quarter of 2022 was $90.6 million, or $1.74 per share.
BEACON Phase 3 pivotal study of tarcocimab tedromer in retinal vein occlusion topline readout was positive.
Tarcocimab tedromer clinical program continued to advance across all ongoing Phase 3 pivotal studies.
The company continued its manufacturing scale up and announced the grand opening of its purpose-built bioconjugation facility with its manufacturing partner Lonza in May 2022.
Pipeline product candidates KSI-501 and KSI-601 continued to progress.
Kodiak Sciences
Kodiak Sciences
Forward Guidance
Full primary results from the BEACON study are expected to be presented by BEACON Study Investigators at upcoming ophthalmology congresses in September 2022.